Avid Bioservices, Inc. (CDMO)

Contract development and manufacturing organization specializing in biopharmaceutical products.

CDMO Stock Quote

Company Report

Avid Bioservices, Inc. operates as a leading contract development and manufacturing organization (CDMO), specializing in biopharmaceutical drug substances derived from mammalian cell culture. Established in 1981 and headquartered in Tustin, California, the company focuses on providing comprehensive process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services.

Central to Avid Bioservices' capabilities is its expertise in producing monoclonal antibodies and recombinant proteins for biopharmaceutical clients. The company offers a full spectrum of services including CGMP manufacturing of drug substances, bulk packaging, release and stability testing, and regulatory submission support. Additionally, Avid Bioservices provides extensive process development services such as upstream and downstream development, optimization, and analytical methods development, ensuring robust and scalable manufacturing processes.

Avid Bioservices serves a diverse client base in the biotechnology and biopharmaceutical industries, collaborating closely to meet stringent regulatory requirements and accelerate the path to clinical trials and commercialization. Its commitment to quality and innovation underscores its reputation as a trusted partner in the development and manufacturing of complex biologics.

Formerly known as Peregrine Pharmaceuticals, Inc., the company rebranded as Avid Bioservices, Inc. in January 2018 to better reflect its focus and expertise in providing comprehensive CDMO solutions. With decades of experience and a state-of-the-art facility, Avid Bioservices continues to play a pivotal role in advancing therapeutic innovations and supporting the growth of biopharmaceutical companies worldwide.

CDMO EPS Chart

CDMO Revenue Chart

Stock Research

PSTX CSV MITQ TMUS TKO ARKO BALL

CDMO Chart

View interactive chart for CDMO

CDMO Profile

CDMO News

Analyst Ratings